Q4 Earnings Forecast for Repligen Issued By Leerink Partnrs

Repligen Corporation (NASDAQ:RGEN) – Equities research analysts at Leerink Partnrs decreased their Q4 2026 earnings per share (EPS) estimates for Repligen in a research report issued to clients and investors on Monday, October 13th. Leerink Partnrs analyst P. Souda now forecasts that the biotechnology company will post earnings per share of $0.60 for the quarter, down from their previous forecast of $0.64. The consensus estimate for Repligen’s current full-year earnings is $1.72 per share.

Other equities analysts also recently issued reports about the company. Jefferies Financial Group decreased their price target on Repligen from $145.00 to $135.00 and set a “hold” rating for the company in a research note on Friday, September 12th. Wall Street Zen upgraded Repligen from a “hold” rating to a “buy” rating in a research note on Saturday, October 11th. HC Wainwright restated a “buy” rating and issued a $180.00 target price on shares of Repligen in a research note on Wednesday, September 3rd. Wells Fargo & Company decreased their target price on Repligen from $180.00 to $175.00 and set an “overweight” rating for the company in a research note on Wednesday, July 30th. Finally, Royal Bank Of Canada restated an “outperform” rating and issued a $205.00 target price on shares of Repligen in a research note on Tuesday, September 2nd. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $169.62.

Repligen Stock Up 3.4%

NASDAQ:RGEN opened at $154.55 on Thursday. The company has a market capitalization of $8.69 billion, a price-to-earnings ratio of -618.18, a price-to-earnings-growth ratio of 2.76 and a beta of 1.08. Repligen has a one year low of $102.96 and a one year high of $182.52. The stock has a 50-day simple moving average of $127.99 and a 200 day simple moving average of $126.16. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.32 and a current ratio of 8.59.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 EPS for the quarter, missing analysts’ consensus estimates of $0.40 by ($0.03). The firm had revenue of $182.37 million during the quarter, compared to analyst estimates of $174.62 million. Repligen had a positive return on equity of 4.61% and a negative net margin of 2.05%.The firm’s revenue for the quarter was up 14.8% on a year-over-year basis. During the same quarter last year, the business posted $0.40 earnings per share. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS.

Insider Activity

In other Repligen news, Director Martin D. Madaus acquired 1,800 shares of Repligen stock in a transaction dated Friday, August 8th. The stock was acquired at an average cost of $112.13 per share, for a total transaction of $201,834.00. Following the completion of the transaction, the director owned 1,800 shares in the company, valued at approximately $201,834. This represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Corporate insiders own 1.20% of the company’s stock.

Institutional Investors Weigh In On Repligen

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. DekaBank Deutsche Girozentrale raised its holdings in Repligen by 1.0% in the second quarter. DekaBank Deutsche Girozentrale now owns 7,830 shares of the biotechnology company’s stock worth $961,000 after purchasing an additional 80 shares during the period. Alliance Wealth Advisors LLC UT raised its holdings in Repligen by 2.5% in the first quarter. Alliance Wealth Advisors LLC UT now owns 3,675 shares of the biotechnology company’s stock worth $468,000 after purchasing an additional 89 shares during the period. Drive Wealth Management LLC raised its holdings in Repligen by 2.5% in the second quarter. Drive Wealth Management LLC now owns 3,796 shares of the biotechnology company’s stock worth $472,000 after purchasing an additional 93 shares during the period. Hilltop National Bank raised its holdings in Repligen by 8.0% in the third quarter. Hilltop National Bank now owns 1,276 shares of the biotechnology company’s stock worth $171,000 after purchasing an additional 95 shares during the period. Finally, ProShare Advisors LLC raised its holdings in Repligen by 4.3% in the second quarter. ProShare Advisors LLC now owns 2,316 shares of the biotechnology company’s stock worth $288,000 after purchasing an additional 96 shares during the period. Institutional investors own 97.64% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.